Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBITDA (2016 - 2025)

Historic EBITDA for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to -$121.6 million.

  • Agios Pharmaceuticals' EBITDA rose 276.64% to -$121.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$472.1 million, marking a year-over-year decrease of 1089.76%. This contributed to the annual value of -$472.1 million for FY2025, which is 1089.76% down from last year.
  • According to the latest figures from Q4 2025, Agios Pharmaceuticals' EBITDA is -$121.6 million, which was up 276.64% from -$116.9 million recorded in Q3 2025.
  • Agios Pharmaceuticals' 5-year EBITDA high stood at -$90.6 million for Q1 2023, and its period low was -$127.1 million during Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' median EBITDA value was -$101.0 million (recorded in 2022), while the average stood at -$102.8 million.
  • As far as peak fluctuations go, Agios Pharmaceuticals' EBITDA plummeted by 11118.96% in 2021, and later surged by 1041.28% in 2023.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' EBITDA stood at -$104.8 million in 2021, then increased by 5.39% to -$99.2 million in 2022, then dropped by 7.16% to -$106.3 million in 2023, then fell by 17.65% to -$125.0 million in 2024, then grew by 2.77% to -$121.6 million in 2025.
  • Its EBITDA was -$121.6 million in Q4 2025, compared to -$116.9 million in Q3 2025 and -$127.1 million in Q2 2025.